CClinicalTrials.gg
CompletedNCT01684605Updated May 23, 2017

Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers

A Phase 1 interventional study of NESP 60μg and CKD-11101 60μg in Anemia, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the pharmacokinetics of CKD-11101 and NESP after IV administration in health male volunteers

Read the detailed description

Healthy volunteers are administrated CKD-11101 60μg and NESP 60μg once intravenously. (crossover) Every time before and after taking each medication, PK parameters and safety of CKD-11101 60μg and NESP 60μg are performed using a blood sample and conducting some tests(Laboratory test, V/S and Physical Examination, etc) respectively.

02

Conditions studied

  • Anemia

Browse trials for

Keywords

  • CKD-11101
  • NESP
  • Darbepoetin alfa
  • Anemia
  • intravenous
  • Pharmacokinetics
  • Phase 1
03

In context

Anemia

1,733 studies on the registry are indexed under Anemia; 246 are open to participants now.

This study's enrollment of 31 is below the median of 94 across 1,291 interventional studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 293 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Signed the informed consent form prior to study participation.
  • A healthy male volunteer between 20 and 55 years old.
  • Body weight between 55kg and 90kg, BMI between 18 and 27.
  • Appropriate subject for the study judging from investigator(physical examination, laboratory test, interview, etc.)

Exclusion criteria

Exclusion Criteria:

  • Have the medical history of allergic diseases including hypersensitivity against drug or clinically significant allergic diseases
  • Clinically significant hepatic, renal, respiratory system, endocrine system, nervous system, immune system, hematologic, psychiatric, circulatory system, tumor or have history of tumor
  • Have abnormal laboratory result.

    • Hemoglobin \< 12g/dL or > 17g/dL
    • Vitamin B12 \< 200pg/mL
    • Ferritin \< 21.8ng/mL
    • Transferrin \< 190mg/dL
    • Reticulocyte over the normal limit
    • Positive for the Triage TOX drug on urine (cocaine, amphetamines, barbiturates, opiates, benzodiazepine, cannabinoids)
    • Positive for HIV antibody, HBsAg, HCV antibody test
  • A heavy smoker (cigarette > 10 cigarettes per day)
  • Administer EPO, darbepoetin, immunoglobulin or IV iron within 3 months prior to the first IP administration
  • Have hypersensitivity reactions history for EPO, darbepoetin, excipient of IP or iron tablets
  • sit SBP \< 90mmHg or sit SBP > 140mmHg or sit DBP \< 55mmHg or sit DBP > 90mmHg or Pulse rate > 100 per/min
  • History of hemoglobinopathy or inflammatory disease or drug abuse within 6 months before screening
  • Subject takes ethical drug or herbal medicine within 14 days, OTC or vitamin supplements within 7 days before the first IP administration
  • Participated in the other clinical trials and administrated IP within 8 weeks prior to the first IP administration
  • A heavy alcohol consumer (alcohol > 21 units/week) or cannot stop drinking
  • Bleed or donate blood (> 400mL) within 8 weeks before the first IP administration
  • Participated in this clinical trials and administrated IP
  • Have a diet within 2 days before the first IP administration or cannot stop having

    • food containing grapefruit
    • food containing caffeine
  • Disagree to avoid getting pregnant during clinical trial
  • An impossible one who participates in clinical trial by investigator's decision including laboratory test result, other reason
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Active comparator
    NESP 60μg

    Prefilled syringe filled with Darbepoetin alfa 60μg

    Drug: NESP 60μg

  • Experimental
    CKD-11101 60μg

    Prefilled syringe filled with Darbepoetin alfa 60μg

    Drug: CKD-11101 60μg

Interventions

  • DrugNESP 60μg

    Administrated NESP 60μg once intravenously

  • DrugCKD-11101 60μg

    Administrated CKD-11101 60μg once intravenously

06

What researchers measure

Primary outcomes

  1. Assess AUClast of darbepoetin alfa

    Time frame: Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h

  2. Assess Cmax of darbepoetin alfa

    Time frame: Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h

Secondary outcomes

  1. Assess AUCinf of darbepoetin alfa

    Time frame: Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h

  2. Assess Tmax of darbepoetin alfa

    Time frame: Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h

  3. Assess t1/2 of darbepoetin alfa

    Time frame: Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h

  4. Assess CL of darbepoetin alfa

    Time frame: Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h

07

Study locations

1 site
  • Seoul national university hospital
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01684605
Lead sponsor
Chong Kun Dang Pharmaceutical
Collaborators
Seoul National University Hospital
Responsible party
Sponsor
First posted
Sep 13, 2012
Start date
Oct 12, 2012
Primary completion
Nov 13, 2012
Completion
Jan 3, 2013
Last update
May 23, 2017

Study contacts

Kyung Sang Yu, Ph.D
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion